Global Age-related Vision Dysfunction Market to 2030 - Insights, Epidemiology, and Forecasts - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Age-Related Vision Dysfunction - Market Insights, Epidemiology, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Age-related Vision Dysfunction market report provides current treatment practices, emerging drugs, Age-related Vision Dysfunction market share of the individual therapies, current and forecasted Age-related Vision Dysfunction market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Age-related Vision Dysfunction treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Findings

In the year 2020, the total prevalent case of Age-related Vision Dysfunction was 374,306,439 cases in the 7MM which are expected to grow during the study period, i.e. 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Age-related Vision Dysfunction epidemiology [segmented as Total Prevalent Cases of Age-related Vision Dysfunction, Total Diagnosed Cases of Age-related Vision Dysfunction, Severity-specific Cases of Age-related Vision Dysfunction, and Treated cases of Age-related Vision Dysfunction] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Age-related Vision Dysfunction Epidemiology

Estimates show that the highest cases of Age-related Vision Dysfunction in the 7MM were in the United States, followed by Japan, Germany, Italy, France, the United Kingdom, and Spain in 2020.

In the United States, the total number of prevalent cases of Age-related Vision Dysfunction was 159,952,427 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.

In the year 2020, the total prevalent cases of Age-related Vision Dysfunction were 168,408,889 cases in EU-5 which are expected to grow during the study period, i.e., 2018-2030.

In Japan, the total number of prevalent cases of Age-related Vision Dysfunction was 45,945,123 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.

Age-related Vision Dysfunction Drug Chapters

The drug chapter segment of the Age-related Vision Dysfunction report encloses the detailed analysis of Age-related Vision Dysfunction marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Age-related Vision Dysfunction clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

The United States Market Outlook

The total market size of Age-related Vision Dysfunction therapies in the United States is expected to increase with a CAGR of 5.4% in the study period (2018-2030).

EU-5 Countries: Market Outlook

The total market size of Age-related Vision Dysfunction therapies in EU-5 countries is expected to increase with a CAGR of 1.8% in the study period (2018-2030).

Japan Market Outlook

The total market size of Age-related Vision Dysfunction therapies in Japan is expected to increase with a CAGR of 0.8% in the study period (2018-2030).

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the Age-related Vision Dysfunction market.
• To understand the future market competition in the Age-related Vision Dysfunction market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Age-related Vision Dysfunction in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Age-related Vision Dysfunction market.
• To understand the future market competition in the Age-related Vision Dysfunction market.

Companies Mentioned

• Adverum Biotechnologies
• Aerpio Pharmaceuticals
• Alkahest
• Alkeus Pharmaceuticals
• Allergan [acquired by AbbVie]
• Allergo Opthalmics
• Baush Health
• Chengdu Kanghong Pharmaceuticals
• Eyenovia
• Graybug Vision
• Gyroscope Therapeutics
• IVERIC Bio
• KalVista Pharmaceuticals
• Kodiak Sciences
• Kubota Vision
• Molecular Partners
• Nicox Ophthalmics
• Novartis
• Ocular Therapeutix
• Ocuphire Pharma
• Opthea
• Orasis Pharmaceuticals
• Outlook Therapeutics
• Regenxbio
• Roche
• Santen Pharmaceutical
• Sun Pharma Advanced Research Company Limited

For more information about this report visit https://www.researchandmarkets.com/r/39zzwu

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900